DiagnoCure Inc. reported consolidated earnings results for the first quarter ended January 31, 2016. Total revenues for the first quarter of 2016 were $134,003 compared with $142,915 for the same period of 2015. Net loss (before transaction fees for the sale of PCA3, stock-based compensation, depreciation and amortization) was $185,757 against $243,291 reported last year.

Net loss and comprehensive loss was $429,655 against $332,271 reported last year. Basic and diluted net loss per share was $0.01 against $0.01 reported last year.